IMAC Holdings Inc. Launches Subsidiary Ignite Proteomics and Announces Groundbreaking Precision Oncology Case Study Utilizing RPPA Technology

Nashville, TN, Sept. 19, 2024 (GLOBE NEWSWIRE) -- IMAC Holdings, Inc. (Nasdaq: BACK) (“IMAC Holdings” or the “Company”), a leader in innovative healthcare solutions, proudly announces the launch of an entirely new precision oncology assay for breast cancer treatment decision making utilizing the Reverse Phase Protein Array (RPPA) technology through its newly established subsidiary, Ignite Proteomics LLC (“Ignite Proteomics”). This launch follows IMAC Holdings’ strategic acquisition of key assets from Theral ...